Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.62 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | MST1R | Q04912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12877852 | 0.88 | MET (0.62) | METPDGFRAKDRPDGFRBPDE4C | |
| SCHEMBL1163419 | 0.84 | MET (0.75) | MET | |
| SCHEMBL28864667 | 0.82 | MET (0.73) | METPDGFRAKDRPDGFRB | |
| SCHEMBL29870110 | 0.82 | MET (0.73) | METPDGFRAKDRPDGFRB | |
| SCHEMBL2571742 | 0.82 | MET (0.66) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL2572032 | 0.82 | MET (0.66) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL2573883 | 0.82 | MET (0.66) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL6524414 | 0.82 | MET (0.75) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL1163610 | 0.80 | MET (0.62) | METPDGFRAKDRKITSRC | |
| SCHEMBL29869981 | 0.78 | MET (0.82) | METPDGFRAKDRKITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| EP-2464649-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION | Novartis AG (CH) | 2012-06-20 | — | — | EP | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| WO-2011018454-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | MET, HGF, RET | MET 1/4885PDGFRA 46/4885KDR 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.